ShangBay Capital

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

Healthcare is extremely inefficient due to complex and disparate systems that don’t talk to each other. The explosion of data further compounds the problem. Huma.AI improves (if not solves) this inefficiency by serving as the connective tissue between system silos allowing “mere mortals” to automatically access data, gain insights and take action using everyday language.

Contraline is developing the first long-lasting, non-hormonal, reversible contraceptive for men

Laplace is a medical device company that develops transcatheter tricuspid valve technology. The company's transcatheter tricuspid valve technology offers an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation.

Fluid Biomed is a medical device start-up focused on creating an implantable dissolving stent for the treatment of brain aneurysms. Founded by neurosurgeons, the company aims to improve patient outcomes by providing a device that promotes healing while minimizing the need for invasive procedures.

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

Neuro42 is developing and commercializing advanced MRI and robotics technology for diagnosis and image-guided interventions.

Emboline is a medical device company with a game-changing device for total embolic protection during percutaneous heart valve repair and replacement procedures and other cardiovascular procedures with embolic risks.

EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform. Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Aqua Medical developed a vapor-based, endoscopic, ablation technology to treat gastrointestinal disease and prevent GI cancers. The company's ablation technology is consists of high-temperature water vapor created by a radiofrequency generator that delivers endoscopically through proprietary catheters to the GI tract. Aqua Medical was founded in 2016 by Virender K. Sharma and is based in Santa Ana, California, United States.

OrthoFX is a San Francisco-based company that delivers a complete clear aligner solution for Doctors (Orthodontists and General Dentists) combined with a superior patient experience.

Zeto is a commercial stage medical technology startup transforming the way EEG (Electroencephalography) is done at hospitals. We are solving a problem unsolved since EEG was invented in 1924, i.e., an archaic, tedious approach that consumes time, requires a trained technician and puts the patient through a poor experience. Our product is the first FDA cleared wireless, zero-prep, easy-to-wear headset with dry electrodes. The device is backed by a digital platform that offers instant upload, tools for analysis, and remote interpretation by neurologists. A process that takes over 30 mins by a technician just to set up will instead take just 5 minutes from putting on the headset to interpretable EEG. Zeto has won several awards including $350,000 from the Epilepsy Foundation, 2018 MedTech Innovator Showcase company, 2018 Exponential Medicine MEDY Outstanding Pitch Award, 2017 Rosenman Innovator by UCSF's QB3.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® radiosurgery platform. ZAP-X incorporates a unique self-shielded design that typically eliminates the need for traditional radiation vaults, and thus enables simple point-of-care delivery in locations previously unfeasible or cost-prohibitive, including physician offices, ambulatory surgery centers, and satellite facilities.

The Aveta™ System is an all-in-one tissue removal solution for intrauterine pathology. Because of its small footprint, it can be equally integrated into any exam, procedure, or operating room—offering patients and physicians more advanced, convenient, and cost-effective procedure options. Wide-angle HD hysteroscopy with electronic upright image-lock, advanced fluid management with improved pressure and fluid deficit control, and the smallest insertion diameter with the largest working channel allows optimized tissue resection.

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.

Corinth MedTech, a small startup company located in Cupertino, CA, and founded in 2014, developed a bipolar transurethral and transcervical resection system intended for endoscopically controlled tissue removal for male patients diagnosed with benign prostatic hyperplasia (BPH), and female patients diagnosed with Abnormal Uterine Bleeding (AUB), fibroids and/or polyps requiring Hysteroscopic tissue removal.

Apostle Inc is a biotechnology company in San Jose, CA, a provider of innovative technologies and services for public health and life sciences. Apostle aims to develop innovative technologies in the space of liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing circulating free DNA (cfDNA) as a biomarker. Apostle’s innovations include Apostle MiniMax, a new scalable and automatable method to efficiently capture cfDNA from a standard blood draw; Apostle MagTouch, a nucleic acids isolation automation system, and Apostle MiniEnrich, a high-resolution DNA size enrichment technology using a magnetic nano-platform. Since 2020, the company has responded to the COVID-19 pandemic to help our community fight together with a high quality, low cost, fast, automated, Apostle COVID-19 Viral RNA Isolation System. Up to date, Apostle’s technology has served over 13 million people. Apostle Diagnostics a CLIA Certified, California State Licensed, CAP Accredited Clinical Laboratory, and is a clinical laboratory branch of Apostle Inc. The laboratory is co-directed by Wenqi Zeng, MD, PhD, FACMG and Charles Strom, MD, PhD, FAAP, FACMG, HCLD. The laboratory upholds the people-oriented and science-oriented service concept and is committed to serving the community and providing accurate, strict and timely clinical testing services. To date, Apostle Diagnostics has served more than 30,000 people.

Atia Medical is a medical device company focusing on advancing eye care through the innovation of ophthalmic devices, diagnostics, and pharmaceuticals. The company is focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer healthier lives. They improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens. Atia Vision modular intraocular lens technology features an accommodating base responsive to the ciliary muscles, simulating the natural mechanism of the eye and fixed lens element that allows for subsequent refractive correction. The company's unique technology enables natural accommodation, utilizing the ciliary muscles of the eye and providing for subsequent refractive correction, to restore the full range of functional vision for cataract patients. Atria Vision was founded in 2012 and is headquartered in Campbell, California, United States.

Berkeley Lights is a provider of research and development services using micro-droplet technology intended to fundamentally change the way biological processes are done. The company's services revolutionize how scientists and researchers study the interaction of cells and transform and accelerate cellular therapies, enabling clients to meet the demands for cell-based processes in biotherapeutic discovery and development, cellular therapy manufacturing, synthetic biology, ag-bio, and other fields.

NeuroVasc Technologies is a medical device company that develops a catheter-based technology designed to treat neurovascular diseases. The company develops a comprehensive portfolio development strategy to bring tools to the community to facilitate treatment options for patients suffering from a stroke. NeuroVasc Technologies was founded in 2015 and is headquartered in Laguna Hills, California.

Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function.

Emboline is a medical device company with a game-changing device for total embolic protection during percutaneous heart valve repair and replacement procedures and other cardiovascular procedures with embolic risks.

Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need.

Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.

Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function.